Open AccessLenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: an initial Russian experience
Author(s) -
Maria Volkova,
O. I. Evsyukova,
A. S. Olshanskaya,
В. Б. Матвеев
Publication year - 2018
Publication title -
onkourologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 4
eISSN - 1996-1812
pISSN - 1726-9776
DOI - 10.17650/1726-9776-2018-14-1-76-86
Subject(s) - medicine , everolimus , lenvatinib , tolerability , renal cell carcinoma , adverse effect , oncology , targeted therapy , combination therapy , temsirolimus , cancer , urology , gastroenterology , discovery and development of mtor inhibitors , apoptosis , biochemistry , chemistry , protein kinase b , thyroid cancer